Blood sugar and insulin sensitivity: Evidence-Based Supplement Guide

Fifteen of the 72 people in Avelor with a saved stack hold something taken for blood sugar. This is the one area in the product where a supplement working is itself a hazard. Everywhere else, a weak effect means wasted money. Here, an effect that lands on top of a glucose-lowering medicine can drive blood sugar too low. That inverts the usual reading of the evidence, and it shapes every section below. The best-evidenced intervention is not a supplement, and it is not close. The Diabetes Prevention Program randomised people at high risk to a structured lifestyle programme, to metformin, or to placebo (PMID 12453955). Its 15-year follow-up reported that both the lifestyle arm and the metformin arm still showed lower diabetes incidence than placebo (PMID 26377054). Nothing in the supplement literature has been tested at that scale or over that horizon. Two smaller findings are also worth more than most of the shelf. A systematic review and meta-analysis examined exercise placed before versus after a meal and its effect on the glucose response (PMID 36715875), and a randomised trial examined interrupting prolonged sitting (PMID 38629807). A separate cohort study using continuous glucose monitoring reported that the same meal produced substantially different responses in different people (PMID 26590418). That is the strongest available argument for measuring your own response rather than trusting a food list. Among supplements, the evidence is unusually well mapped and mostly disappointing. Berberine has the strongest signal. It has a randomised trial in newly diagnosed type 2 diabetes (PMID 18442638) and a systematic review and meta-analysis of randomised trials (PMID 34956436). A further randomised trial combined it with probiotics (PMID 33024120). An umbrella review graded the certainty of berberine's reported effects across outcomes (PMID 36999891). It is the more reliable summary because it pools the meta-analyses and grades them, so a single favourable trial cannot carry the conclusion on its own. Cinnamon has been reviewed repeatedly with conflicting results, including an early randomised trial (PMID 14633804), a systematic review that did not resolve the question (PMID 24019277), and an updated dose-response meta-analysis (PMID 37818728). Chromium has an extensive systematic review (PMID 39541030), a meta-analysis in type 2 diabetes (PMID 33783683), and a network meta-analysis comparing micronutrients against each other (PMID 36638933). Inositol is the one case with a guideline behind it. The systematic review that informed the 2023 international PCOS guidelines covers it (PMID 38163998). It also has a randomised trial against metformin (PMID 37265016) and a network meta-analysis of insulin sensitisers (PMID 34407851). Soluble fibre has a meta-analysis in type 2 diabetes (PMID 33162192) and psyllium has one reporting effects that scale with how poor glycaemic control was to begin with (PMID 26561625). Two things commonly sold for blood sugar are not supported for it. Vitamin D has been tested directly and repeatedly for preventing progression to type 2 diabetes. A large randomised trial examined it (PMID 31173679). So did a second trial using an active analogue (PMID 35613725), and an ancillary analysis of a general-population trial (PMID 40199888). A randomised trial combining vitamin D with magnesium reported no effect on glycaemic control (PMID 36640582). Alpha-lipoic acid has a meta-analysis, but for diabetic polyneuropathy symptoms rather than for blood sugar itself (PMID 37630823). It belongs in a nerve-pain conversation with a clinician, not a glucose one.

1. **Establish what your numbers actually are with whoever manages your care.** Every step below assumes you know whether you are managing prediabetes, type 2 diabetes, PCOS, or a normal result you want to keep. 2. **Put the lifestyle programme first.** It is the intervention with 15-year randomised follow-up (PMID 26377054, 12453955), and it is the comparator every supplement below is being measured against. 3. **Move after meals rather than before them where you can.** This is the variable the timing meta-analysis examined directly (PMID 36715875), and breaking up long sitting was tested as its own action (PMID 38629807). 4. **Add soluble fibre before adding an active compound.** It has meta-analytic support (PMID 33162192, 26561625) and it does not carry the hypoglycaemia stacking problem in the same way. 5. **Treat your own response as the measurement.** Individual responses to identical meals differ (PMID 26590418). 6. **Only then consider berberine or inositol**, and only after the cautions section, because both are being taken for their effect on the same system a medicine may already be acting on.

Where the research supports a timeframe, the Diabetes Prevention Program reported outcomes over **three years** and its outcomes study followed participants for **15 years** (PMID 12453955, 26377054). The berberine trial in newly diagnosed type 2 diabetes ran over **three months** (PMID 18442638). The exercise findings are **acute**: the timing meta-analysis and the sitting trial both measured the glucose response around a single meal or a single session (PMID 36715875, 38629807). No duration is given for chromium or cinnamon, because the reviews do not converge on an effect for which a duration would be meaningful.

- **Most of this evidence is in people who already have type 2 diabetes or PCOS.** If your numbers are normal and you are trying to keep them there, the supplement trials above were not run in you. The lifestyle evidence was run in people at high risk rather than at average risk. - **Berberine's evidence base is real but graded low in places.** The umbrella review exists precisely because single trials read stronger than the pooled certainty supports (PMID 36999891). This guide cites it rather than the most favourable trial. - **Cinnamon does not resolve.** Three reviews across two decades reach different conclusions (PMID 14633804, 24019277, 37818728). That is not a reason to call it promising. It is a reason to say the question is open. - **Chromium is close to settled in the unhelpful direction.** The extensive systematic review and the network meta-analysis do not support it as a glycaemic intervention (PMID 39541030, 36638933). - **Inositol's guideline support is for PCOS, not for blood sugar generally** (PMID 38163998). Reading it across to type 2 diabetes is not something the cited evidence does. - **Vitamin D has been tested and did not deliver here.** Three randomised datasets are cited above rather than one, because a single null result is easier to dismiss than three (PMID 31173679, 35613725, 40199888). - **No head-to-head trial compares any of these supplements against the lifestyle programme.** The comparison implied by putting them in the same guide has not been run.

- **Anything that lowers blood sugar can lower it too far when you are already on a medicine that does.** This applies to insulin and to sulfonylureas in particular. Before adding berberine, inositol, or any product marketed for glucose support, raise it with **the clinician or prescriber who manages your diabetes medicines**, and ask what your monitoring should look like while you start. A comprehensive care guideline exists for exactly this planning conversation (PMID 35963508). - **Do not stop, reduce, or reschedule a prescribed glucose-lowering medicine because a supplement seems to be working.** That decision belongs to **your prescriber**, and the risk of getting it wrong is immediate rather than gradual. - **If you take metformin, vitamin B12 is a real and separate issue.** Metformin interferes with B12 absorption, and the resulting deficiency can cause or worsen neuropathy (PMID 35491956). Screening and management guidance exists (PMID 28925645). Raise it with **your prescriber** rather than self-treating, because the symptoms overlap with diabetic neuropathy itself. - **Cassia cinnamon carries coumarin, which is a liver concern rather than a glucose one** (PMID 19680836). Anyone taking cinnamon as a supplement rather than as a spice should raise it with **a pharmacist or clinician**, particularly alongside any other medicine processed by the liver. - **Anyone who is pregnant or planning pregnancy should route this entire guide through their obstetric clinician first.** Gestational glucose management is a different clinical problem. None of the supplement evidence above was derived in it. - **Symptoms that are new or getting worse are a reason to see a clinician**, not a reason to add another supplement. Unexplained thirst, unexplained weight change, blurred vision, or numbness and tingling in the feet all belong with **a doctor**.

Resolving to an entity and being interaction-checkable are different things, and this guide originally conflated them. The interaction catalogue keys on a collapsed name string, not on an entity id: all 504 catalogue rows, and 0 of them join to `registry_entities` by id. So there are three states, not two. Resolves to a supplement entity **and** has a catalogue key, so it can be interaction-checked: - `avelor:sup:berberine` - `avelor:sup:alpha-lipoic-acid` - `avelor:sup:cinnamon` - `avelor:sup:chromium` - `avelor:sup:cyanocobalamin`, `avelor:sup:methylcobalamin`, `avelor:sup:adenosylcobalamin` Resolves to a supplement entity but has **no catalogue key**, so it displays as a recognised ingredient and is checked against nothing: - `avelor:sup:inositol` - `avelor:sup:psyllium-husk` These do not, and no ID is invented for them here: - **Vitamin D** has no `supplement_compound` entity. It exists only as `avelor:med:vitamin-d`, a medication. The three randomised trials cited above studied it as a supplement, so the guide's most strongly evidenced negative finding cannot be attached to a supplement entity. - **Magnesium** has no plain `supplement_compound` entity either. Only `avelor:sup:magnesium-l-threonate` exists, which is a specific form and not the one used in the cited trial. - **Soluble fibre** as a category has no entity. Only the psyllium form does. - **Metformin** resolves as `avelor:med:metformin`, a medication rather than a supplement. The B12 caution above is therefore a medicine-to-supplement relationship that the supplement interaction checker is not positioned to surface. One search-layer defect found while reconciling this guide, recorded rather than fixed here: the string `myo-inositol` matches `avelor:sym:hp0034610`, an HPO **symptom** entity, before it reaches `avelor:sup:inositol`. A picker that resolves on display-name match would offer a symptom where the user meant a supplement.

| PMID | Title | | --- | --- | | 12453955 | "The Diabetes Prevention Program (DPP): description of lifestyle intervention" | | 26377054 | "Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study" | | 36715875 | "After Dinner Rest a While, After Supper Walk a Mile? A Systematic Review with Meta-analysis on the Acute Postprandial Glycemic Response to Exercise Before and After Meal Ingestion in Healthy Subjects and Patients with Impaired Glucose Tolerance" | | 38629807 | "Enhanced muscle activity during interrupted sitting improves glycemic control in overweight and obese men" | | 26590418 | "Personalized Nutrition by Prediction of Glycemic Responses" | | 33162192 | "Effects of soluble fiber supplementation on glycemic control in adults with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials" | | 26561625 | "Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus" | | 18442638 | "Efficacy of berberine in patients with type 2 diabetes mellitus" | | 34956436 | "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" | | 33024120 | "Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)" | | 36999891 | "Berberine and health outcomes: An umbrella review" | | 39541030 | "Chromium supplementation and type 2 diabetes mellitus: an extensive systematic review" | | 33783683 | "Effect of Chromium Supplementation on Blood Glucose and Lipid Levels in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-analysis" | | 36638933 | "Comparative effects of vitamin and mineral supplements in the management of type 2 diabetes in primary care: A systematic review and network meta-analysis of randomized controlled trials" | | 14633804 | "Cinnamon improves glucose and lipids of people with type 2 diabetes" | | 24019277 | "Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis" | | 37818728 | "The effect of cinnamon supplementation on glycemic control in patients with type 2 diabetes mellitus: An updated systematic review and dose-response meta-analysis of randomized controlled trials" | | 38163998 | "Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines" | | 37265016 | "A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome" | | 34407851 | "Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis" | | 31173679 | "Vitamin D Supplementation and Prevention of Type 2 Diabetes" | | 35613725 | "Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population" | | 40199888 | "Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial" | | 36640582 | "Combined vitamin D and magnesium supplementation does not influence markers of bone turnover or glycemic control: A randomized controlled clinical trial" | | 37630823 | "Effects of Oral Alpha-Lipoic Acid Treatment on Diabetic Polyneuropathy: A Meta-Analysis and Systematic Review" | | 35491956 | "Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes" | | 28925645 | "Vitamin B12 Deficiency: Recognition and Management" | | 19680836 | "Coumarin and cinnamaldehyde in cinnamon marketed in Italy: a natural chemical hazard?" | | 35963508 | "American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update" |